Difficult decisions in the cost-effectiveness analysis of new cancer treatments

被引：0
|
作者：
Willemse, Pax H. B. [1 ]
Tjan-Heijnen, Vivianne C. G. [2 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Oncol, NL-9700 RB Groningen, Netherlands
[2] Maastricht Univ, Med Ctr, NL-6202 AZ Maastricht, Netherlands
来源：
EJHP PRACTICE | 2009年 / 15卷 / 04期
关键词：
CLINICAL-TRIALS;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The value of cancer treatment varies. In The Netherlands ENDO was formed to reach consensus on the value of treatment with a newly developed tool. Professors Willemse and Tjan-Heijnen, former chairs of this committee, together look at the intrinsic difficulties of valuing new cancer treatments.
引用
收藏
页码：50 / 53
页数：4
相关论文
共 50 条
  • [21] Cost-effectiveness of treatments of hypertension
    Rubió, PP
    MEDICINA CLINICA, 2000, 115 (18): : 718 - 718
  • [22] An analysis of the cost-effectiveness of rigid pavement rehabilitation treatments
    Khurshid, Muhammad Bilal
    Irfan, Muhammad
    Labi, Samuel
    STRUCTURE AND INFRASTRUCTURE ENGINEERING, 2011, 7 (09) : 715 - 727
  • [23] Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder
    Rendas-Baum R.
    Yang M.
    Gricar J.
    Wallenstein G.V.
    Applied Health Economics and Health Policy, 2010, 8 (2) : 129 - 140
  • [24] Cost-effectiveness analysis of current varicose veins treatments
    Epstein, David
    Bootun, Roshan
    Diop, Modou
    Ortega-Ortega, Marta
    Lane, Tristan R. A.
    Davies, Alun H.
    JOURNAL OF VASCULAR SURGERY-VENOUS AND LYMPHATIC DISORDERS, 2022, 10 (02) : 504 - +
  • [25] Cost-effectiveness analysis of treatments for vertebral compression fractures
    Edidin A.A.
    Ong K.L.
    Lau E.
    Schmier J.K.
    Kemner J.E.
    Kurtz S.M.
    Applied Health Economics and Health Policy, 2012, 10 (4) : 273 - 284
  • [26] A cost-effectiveness analysis of biological treatments for rheumatoid arthritis
    Chiou, CF
    Wanke, L
    Yu, E
    Ofman, J
    VALUE IN HEALTH, 2004, 7 (03) : 223 - 223
  • [27] A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence
    Woods, Beth
    Palacios, Alfredo
    Sculpher, Mark
    PHARMACOECONOMICS, 2024, : 363 - 373
  • [28] Hospital pharmacy decisions, cost containment, and the use of cost-effectiveness analysis
    Sloan, FA
    WhettenGoldstein, K
    Wilson, A
    SOCIAL SCIENCE & MEDICINE, 1997, 45 (04) : 523 - 533
  • [29] COST-EFFECTIVENESS ANALYSIS OF A NEW INDEX FOR PROSTATE CANCER DETECTION
    Nichol, M. B.
    Wu, J.
    An, J. J.
    Huang, J. T.
    Denham, D.
    Frencher, S. K.
    Jacobsen, S. J.
    VALUE IN HEALTH, 2011, 14 (03) : A82 - A82
  • [30] Considerations for modeling the cost-effectiveness of preventative prostate cancer treatments
    Bell, C. F.
    McDade, C. L.
    Black, L.
    Earnshaw, S. R.
    Kattan, M. W.
    VALUE IN HEALTH, 2008, 11 (03) : A61 - A61
12345